Edesa Biotech (EDSA)

• Market cap: $5.79M
• 1 day: -3.47%
• 5 days: -8.74%
• 1 month: -22.33%
• 3 months: -62.30%
• 6 months: -61.87%
• Year to date: -64.32%
• 1 year: -65.64%
• 5 years: -94.20%
• 10 years: -99.64%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Employees: 16

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

11% more capital invested

Capital invested by funds: $645K [Q2] → $718K (+$73K) [Q3]

0.28% more ownership

Funds ownership: 4.68% [Q2] → 4.96% (+0.28%) [Q3]

0% more funds holding

Funds holding: 17 [Q2] → 17 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1